What SEC filings does BioCryst Pharmaceuticals, Inc. submit to the SEC?

BioCryst Pharmaceuticals, Inc. (BCRX) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about BCRX?

A Form 4 for BCRX discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from BioCryst Pharmaceuticals, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for BCRX?

The 10-K is BioCryst Pharmaceuticals, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all BCRX SEC filings directly on EDGAR?

You can view all historical BioCryst Pharmaceuticals, Inc. filings on the SEC EDGAR company page for BCRX. Each filing card on this page links directly to the original SEC document.

How often does BioCryst Pharmaceuticals, Inc. file with the SEC?

BioCryst Pharmaceuticals, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling BCRX shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

BCRX SEC Filing News — BioCryst Pharmaceuticals, Inc.

Latest SEC filings for BioCryst Pharmaceuticals, Inc. (BCRX) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-02.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in …

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic Market Cap: $2.1B CIK: 882796

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by BioCryst Pharmaceuticals, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

BCRX Filing Activity Snapshot 2026-06-02 — 2026-09-02

Insider Transactions (Form 4)

0 buys vs 0 sells

Insider buying and selling activity is balanced in this period.

Insider Transactions 15 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 15 filings in this group are Form 4s for BioCryst Pharmaceuticals, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 15 insider filings shown, the breakdown is 15 compensation award. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×15: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Form 4 Compensation award Tax / Compensation Filing 2026-09-02

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Stonehouse Jon P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	644	$9.70	$6.2K

Filing: Form 4 (Insider Transaction) Insider: Stonehouse Jon P (Director) Shares: 644

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-02

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Milne Jill C. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,288	$9.70	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Milne Jill C. (Director) Shares: 1,288

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-02

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

MILANO VINCENT (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,159	$9.70	$11.2K

Filing: Form 4 (Insider Transaction) Insider: MILANO VINCENT (Director) Shares: 1,159

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-02

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

McKee Amy E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	644	$9.70	$6.2K

Filing: Form 4 (Insider Transaction) Insider: McKee Amy E (Director) Shares: 644

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-09-02

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Frank Steven (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,288	$9.70	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Frank Steven (Director) Shares: 1,288

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Milne Jill C. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: Milne Jill C. (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Galson Steven K (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: Galson Steven K (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

LEVIN ALAN G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: LEVIN ALAN G (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Frank Steven (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: Frank Steven (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

SANDERS MACHELLE (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: SANDERS MACHELLE (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

MILANO VINCENT (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: MILANO VINCENT (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Stonehouse Jon P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: Stonehouse Jon P (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

McKee Amy E (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: McKee Amy E (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

HEGGIE THERESA (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	15,294	—	—
`A`	Compensation award derivative · Automatic Stock Option Grant	33,540	—	—

Filing: Form 4 (Insider Transaction) Insider: HEGGIE THERESA (Director) Shares: 15,294

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-02

BCRX insider Form 4 filed for equity award, exercise, or tax withholding

Milne Jill C. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	1,262	$8.91	$11.2K

Filing: Form 4 (Insider Transaction) Insider: Milne Jill C. (Director) Shares: 1,262

View on SEC EDGAR → Open Filing Document →

Material Events 4 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 4 in this period for BioCryst Pharmaceuticals, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-05

BCRX filed 8-K — material company event

BIOCRYST PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K/A Amended Material Company Update 2026-08-04

BCRX filed amended 8-K — material company event

BIOCRYST PHARMACEUTICALS INC filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-29

BCRX filed 8-K — material company event

BIOCRYST PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-06-12

BCRX filed 8-K — material company event

BIOCRYST PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for BioCryst Pharmaceuticals, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-05

BCRX filed Quarterly Report (10-Q)

BIOCRYST PHARMACEUTICALS INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify BioCryst Pharmaceuticals, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on BCRX. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — BCRX SEC Filings

More Tools for BCRX

BCRX Full Stock Analysis BCRX Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper BCRX analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the BCRX stock analysis page.

BCRX Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer